TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Role Functioning Rating Scale (RFRS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline in the PDDBI - Autism Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in the BASC-2 - Externalizing Problems Composite
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ICU eligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lung Deposition - Penetration Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sputum induction success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cardiovascular risk identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strength evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CRKP carriage at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: rate of complications following surgery for complicated appendicitis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Post Chemotherapy Surgical Debulking
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Dose Modifications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients presenting with preoperative hypovolemia/reduced BV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with low/very low PPI (PII<1.4 and < 0.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who respond to a 250 ml fluid challenge with sustained rise in SV by at least 10%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of diaphragm thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of diaphragm delta tdi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inclusion in at least one Clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the concentration-time curve (AUC) of the analytes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of the analytes in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of PD-0332991
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance between FFOCT findings and pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage Change in eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of LY2140023
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY2140023
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of LY404039 (Active Moiety)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-inf]) of LY404039 (Active Moiety)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily active energy expenditure during working time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Average daily physical activity duration at different intensities during working time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average daily number of steps during working time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the hypodermis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area of indentations reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Erectile Dysfunction Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological adaptation to high altitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in weekly frequency of moderate to severe vasomotor symptoms (VMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in severity of moderate to severe vasomotor symptoms (VMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with severe adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants discontinuing study intervention due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants experiencing adverse events and/or treatment limiting-toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of tumor-specific immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fractional Inhibitory Concentration Index (FICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in APAIS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 2 year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: 2 year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of lymphoma specific mutations or detectable IgH rearrangements in circulating tumor specific DNA in blood samples at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: hemoglobin levels at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: oxidized albumin levels at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered pulmonary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ordinal severity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in mood scales
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Door to balloon time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Probability of invasive candidiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Test performance of clinical predictive model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in use of oxytocin for prevention of postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Sensitivity of BD SurePath Plus Pap Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of BD SurePath Plus Pap Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PPV of BD SurePath Plus Pap Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPV of BD SurePath Plus Pap Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height of incongruity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best corrected visual acuity (bcva)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin K levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: En Bloc Resection Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complication-Free Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Spinal anesthesia success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of recurrent corneal epithelium exfoliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prealbumin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in mean haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical malaria incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Pathologic complete response rate (pCR) in patients with stage III BRAFm melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic complete response rate in patients with stage III BRAFwt melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Median recurrence-free survival (RFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Safety assessed by vital signs and incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor response assessed by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Maximum Eosinophil Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of catecholamine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cannulation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Dose of sedation medication used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nutritional adequacy for normal growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment related grade 3 or higher non-hematologic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Knee pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation-recovery intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visibility of ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Processing of Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamstring muscles thickness by Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hamstring muscles thickness by Magnetic Resonance Image
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ADHD Rating Scale-IV checklist, school version
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomechanics of the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes of foot joint angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: senior fitness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of emotional memory functions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of episodic memory functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvement in Psoriasis Area and Severity Index (PASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: HIV drug resistant mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caspase-8 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Habitual Activity Estimation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total antibiotic usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: adherence to device
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occurrence of symptomatic intracerebral hemorrhage (SICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients reaching adequate serum 25(OH)D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persisting hSBA Titers ≥1:8 Against Neisseria Meningitidis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of time above MIC or EUCAST breakpoints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of methicillin- and gentamicin resistant microbiological agents in sternal wound infections
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of automatic classification in AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of automatic classification in NSR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Drinks Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported negative mood symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Self-reported subjective state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Threat bias, or dysregulated attention towards threat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Cancer Diagnosis at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Change in General Social Outcomes Measure (GSOM) Assessment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Presence of surgical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change From Baseline in FEV1 AUC3-7hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of anterior chamber cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of keratic precipitates (KP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of vitreous cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Degree of anterior chamber flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reduction in Albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: TME-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Nerve conduction measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain scores from patient diaries
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Magnitude Value of Harmonic Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase Value of Harmonic Effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum concentration of the analyte in plasma (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration time curve over the dosing interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HOMA test of insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heat pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of yttrium Y 90 basiliximab
Endpoint domain: Adverse events/effects
Primary endpoint: VAS score based on TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of inferior turbinate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PNIF value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive IgM/IgG tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgM/IgG positive participants on follow-up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prediction of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in spontaneous pharyngeal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pharyngeal pain on deglutition (dysphagia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pharyngeal hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in systemic manifestations (fever, adenomegaly and general malaise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contingent Negative Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatosensory Evoked Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pneumonia colonized by vaccine-type Streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Community carriage of vaccine-type Streptococcus pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pneumonia and IPD cost of illness
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of Belching and Retching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of lung consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Self-rated Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 14 days readmission to geriatric ward
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time of pronuclear appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of axitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum volume ingested at nutrient drink test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric emptying rate for liquids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric emptying rate for solids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Attendance of ≥ 2 Curves sessions/week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Increase in fruit and vegetable consumption by 1 full serving per day OR reduce caloric intake by 100 kcal/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of intraday FEV1 declines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Freedom from ipsilateral breast recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Self-reported oral health needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Importance of key oral health indicators
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Breast Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: implant stability analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pink and white esthetic score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of non-progressors and recovers of AIDS patients with PML in 6 months
Endpoint domain: Mortality/survival
Primary endpoint: rate of non-progressors and recovers of AIDS patients with PML in 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Area under the concentration versus time curve of raltegravir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes-related Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forced expiratory volume, 1st second in litres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced vital capacity in litres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in cosmetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of BCL-t or cyclin D1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Unprotected Anal Intercourse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Total Unprotected Anal Intercourse Partners
Endpoint domain: Adverse events/effects
Primary endpoint: Unprotected Anal Intercourse Episodes With Three Most Recent Sex Partners
Endpoint domain: Adverse events/effects
Primary endpoint: Relief of symptoms of D-IBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes